Nephrobesity describes the study and care of kidney disease as it relates to obesity. It is an emerging clinical focus — not an accredited board subspecialty — that sits deliberately across two disciplines historically managed apart.

A bidirectional relationship

Obesity and kidney disease drive each other. Excess adiposity raises glomerular pressure and filtration, activates the renin–angiotensin system, and promotes the inflammation and insulin resistance that injure the nephron over years. Kidney disease, in turn, alters metabolism, appetite regulation, and the safe use of weight-management therapies. Understanding the loop in both directions is the starting point of the field.

Obesity-related glomerulopathy (ORG)

The most direct kidney lesion of obesity is obesity-related glomerulopathy: enlarged glomeruli (glomerulomegaly) with an adaptive form of focal segmental glomerulosclerosis, driven by hyperfiltration. It typically presents with slowly rising proteinuria and preserved albumin, and can be misclassified as primary FSGS when the biopsy pattern is read without integrating clinical context, albumin level, the absence of nephrotic syndrome, and the hyperfiltration phenotype. Not all obesity-associated CKD is ORG — but distinguishing the two changes both prognosis and treatment.

The cardiovascular-kidney-metabolic (CKM) framework

Contemporary guidelines increasingly organise these conditions as a single continuum — cardiovascular-kidney-metabolic health — rather than as separate silos of heart, kidney, and metabolic disease. The CKM framework reflects the shared drivers of obesity, dysglycemia, and vascular injury, and it is the conceptual backbone of how Nephrobesity approaches prevention and therapy.

The therapeutic turn — and the renal-safety gap

The last few years reset what is possible. Semaglutide (in the FLOW trial), SGLT2 inhibitors, and the non-steroidal mineralocorticoid-receptor antagonist finerenone each moved from glucose-lowering or blood-pressure drugs to renoprotective therapies backed by dedicated kidney-outcome trials. Kidney-outcome evidence is agent- and endpoint-specific, however, and should not be generalised to the whole GLP-1 class. Dual GIP/GLP-1 agonists show promising but still emerging renal signals; triple agonists and amylin analogs remain investigational. Together these support an emerging multi-pillar approach to cardio-reno-metabolic protection.

But the trials do not close every question, and this is where the discipline earns its name. Dose de-indexing in advanced CKD, renal-safety surveillance during rapid weight loss, electrolyte and acid–base effects, and rare but serious events — euglycemic ketoacidosis with SGLT2 inhibitors, oxalate nephropathy after malabsorptive surgery — sit precisely between what general nephrology and what endocrinology or obesity-medicine training cover in depth. Neither field owns the failing nephron and the incretin at once.

The defining competencies

• 1

  Incretin & CRM pharmacology with renal safety

  Using GLP-1 and SGLT2 agents for their kidney and cardiovascular benefit while managing dose, monitoring, and adverse events in impaired kidney function.

• 2

  The protein dilemma

  Reconciling the protein needs of CKD, dialysis, and transplant patients with the nutritional demands of intentional weight loss.

• 3

  Four-pillar kidney protection

  Integrating RAS blockade, SGLT2 inhibition, GLP-1 agonism, and non-steroidal MRAs into a coherent protective strategy.

• 4

  Diagnosis when creatinine misleads

  Estimating GFR reliably across extremes of muscle mass using cystatin C and the combined creatinine–cystatin equations.

• 5

  Weight management in dialysis and transplant

  Applying obesity therapy in the specific contexts of kidney replacement and transplantation, where the rules differ.

These five competencies open onto ten clinical domains — from the obesity–kidney axis and GFR estimation to metabolic surgery, transplant, dialysis, and special populations. The full map lays out the ground the discipline covers.